Metaxalone-cyclodextrin Loaded Starch Nanocrystal Based Formulation Design, Development and Control Release Evaluation

Nadir Khan; Saurabh Srivastava

doi:10.52711/0974-360X.2026.00183

Research Journal of Pharmacy and Technology

ISSN

0974-360X (Online)
0974-3618 (Print)

Submit Article

Metaxalone-cyclodextrin Loaded Starch Nanocrystal Based Formulation Design, Development and Control Release Evaluation

Author(s): Nadir Khan, Saurabh Srivastava

Email(s): khannadir565@gmail.com

DOI: 10.52711/0974-360X.2026.00183

Address: Nadir Khan*, Saurabh Srivastava
Department of Pharmacy, Ayush and Health Sciences University of Chhattisgarh, Raipur 492001, Chhattisgarh, India.
*Corresponding Author

Published In: Volume - 19, Issue - 3, Year - 2026

View HTML

Purchase PDF

ABSTRACT:
Objective: Nanotechnology enhances the solubility, bioavailability and the rate of solubility of drugs whose solubility of water is very weak. The primary goals of creating nanocrystals are to enhance the bioavailability of weakly soluble drugs, streamline the administration of Metaxalone (MTX) via the all routes and enhance solubility and pharmacokinetic performance. Material and Methods: The solvent diffusion approach was utilized to create drug nanocrystals without surfactants by employing stabilizers such cyclodextrin (CD). A cooling centrifuge was utilized to perform high-speed centrifugation in order to separate the nanocrystal from the nanosuspension. Differential scanning calorimetry (DSC), electron microscopy (SEM), FTIR analysis, powder X-ray diffraction analysis, solubility analysis, Particle size range and zeta potential measurement, in-vitro dissolution and ex-vivo permeation study were used to evaluate and characterized the results. Results: MTX nanocrystal formulation 8 (MNC 8) has better solubility than MNC 7. The nanocrystal was created in MNC 7, MNC 8, and MNC 9, according to the z-average values 448 to 11850nm and zeta potential value for MNC 8 and MNC 7 was found -8.62±3.99 and -10.4±9.13. FTIR spectrum of MNC 8, characteristic peaks that were seen at 3441, 1733, 1082, 3602, 2922, 1641 and 2354 cm-1. In its crystal state, MNC 8 diffraction angles were determined to be 5.01, 10.25, 13.34, 14.18, 17.87, 19.03 and 22.40º. The endothermic peak of DSC at 124ºC confirms the observed melting point of MTX, which is 121ºC. According to DSC thermograms, the melting point range was 120-125ºC. Drugs demonstrated 11% membrane penetration at 1 hour, but MTX permeability through MTX nanocrystals was 15-17%. Better MTX nanocrystal solubility was confirmed at 6 hours with a 46% drug release in MTX solution and a 58-65% drug release in the formulation. MNC 8 exhibited a higher drug content than MNC 7 and MNC 9 among the formulations. Conclusion: Franz diffusion cell apparatus used a biological membrane (egg cell membrane) to conduct an ex-vivo drug release research of MTX and MTX nanocrystal. Compared to pure MTX, formulated MTX nanocrystal exhibits superior drug release.

Keywords:

Cite this article:
Nadir Khan, Saurabh Srivastava. Metaxalone-cyclodextrin Loaded Starch Nanocrystal Based Formulation Design, Development and Control Release Evaluation. Research Journal Pharmacy and Technology. 2026;19(3):1282-8. doi: 10.52711/0974-360X.2026.00183

Cite(Electronic):
Nadir Khan, Saurabh Srivastava. Metaxalone-cyclodextrin Loaded Starch Nanocrystal Based Formulation Design, Development and Control Release Evaluation. Research Journal Pharmacy and Technology. 2026;19(3):1282-8. doi: 10.52711/0974-360X.2026.00183 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2026-19-3-44

REFERENCES:
1. Patel SR. Shah DP. A Review on Nanocrystals Drug Delivery System. Research J. Pharm. and Tech. 2016; 8(5): 647-654. doi.org/10.5958/0974-360X.2015.00103.1
2. Kumar PR. Vijaya Lakshmi A. An Overview on Nanobased Drug Delivery System. Research J. Pharm. and Tech. 2020; 13(10): 4996-5003. doi.org/10.5958/0974-360X.2020.00875.6
3. Gigliobianco MR. Casadidio C. Censi R. Di Martino P. Nanocrystals of Poorly Soluble Drugs: Drug Bioavailability and Physicochemical Stability. Pharmaceutics. 2018; 10(3): 134. doi:10.3390/pharmaceutics10030134
4. Tuomela A. Hirvonen J. Peltonen L. Stabilizing Agents for Drug Nanocrystals: Effect on Bioavailability. Pharmaceutics. 2016; 8(2): 16. doi:10.3390/pharmaceutics8020016
5. Krishnan RP. Sivakumar R. Nanotechnology: Modern Formulation and Evaluation Techniques - An Overview. Research J. Pharm. and Tech. 2019; 12(8): 4039-4044. doi.org/10.5958/0974-360X.2019.00696.6
6. Kalimuthu S. Yadav AV. Nanobased Drug Delivery System: A Review. Research J. Pharm. and Tech. 2009; 2(1): 21-27.
7. Sujan MN. Patil AV. Gowda DV. A Review on Methods of Preparation and Characterization of the solid Lipid Nanoparticles. Research J. Pharm. and Tech. 2020; 13(7): 3433-3441. doi.org/10.5958/0974-360X.2020.00610.1
8. Hao L. Wang X. Zhang D. Xu Q. Song S. Zhang Q. Studies on the preparation, characterization and pharmacokinetics of Amoitone B nanocrystals. Int J Pharm. 2012; 433(1-2): 157-164. doi:10.1016/j.ijpharm.2012.05.002
9. Patel VR. Agrawal YK. Nanosuspension: An approach to enhance solubility of drugs. J Adv Pharm Technol Res. 2011; 2(2): 81-87. doi:10.4103/2231-4040.82950
10. Kumari L. Choudhari Y. Patel P. Gupta GD. Singh D. Kurmi BD. Advancement in Solubilization Approaches: A Step towards Bioavailability Enhancement of Poorly Soluble Drugs. Life (Basel). 2023; 13(5): 1099. doi:10.3390/life13051099
11. Muhesen RA. Rajab NA. Formulation and Characterization of Olmesartan medoxomil as a Nanoparticle. Research J. Pharm. and Tech. 2023; 16(7): 3314-0. doi.org/10.52711/0974-360X.2023.00547
12. Chakravorty R. Nanosuspension as an emerging Nanotechnology and Techniques for its Development. Research J. Pharm. and Tech. 2022; 15(1): 489-493. doi.org/10.52711/0974-360X.2022.00079
13. Sharma D. Soni M. Kumar S. Gupta GD. Solubility Enhancement-Eminent Role in Poorly Soluble Drugs. Research J. Pharm. and Tech. 2009; 2(2): 220-224.
14. Rizwan MI. Damodharan N. Mathematical Modeling of Dissolution Kinetics in Dosage forms. Research J. Pharm. and Tech. 2020; 13(3): 1339-1345. doi.org/10.5958/0974-360X.2020.00247.4
15. Jacob S. Nair AB. Shah J. Emerging role of nanosuspensions in drug delivery systems. Biomater Res. 2020; 24: 3. doi:10.1186/s40824-020-0184-8
16. Dizaj SM. Vazifehasl Zh. Salatin S. Adibkia Kh. Javadzadeh Y. Production of nanosuspensions as a tool to improve drug bioavailability: focus on topical delivery. Curr Pharm Des. 2015; 21(42): 6089-6103. doi:10.2174/1381612821666151027152350
17. Zhang J. Huang Y. Liu D. Gao Y. Qian S. Preparation of apigenin nanocrystals using supercritical antisolvent process for dissolution and bioavailability enhancement. Eur J Pharm Sci. 2013; 48(4-5): 740-747. doi:10.1016/j.ejps.2012.12.026
18. Ran Q. Wang M. Kuang W. Ouyang J. Han D. Gao Z. Gong J. Advances of Combinative Nanocrystal Preparation Technology for Improving the Insoluble Drug Solubility and Bioavailability. Crystals. 2022; 12(9): 1200. doi.org/10.3390/cryst12091200
19. Chen C. Wang L. Cao F. Miao X. Chen T. Chang Q. Zheng Y. Formulation of 20(S)-protopanaxadiol nanocrystals to improve oral bioavailability and brain delivery. Int J Pharm. 2016; 497(1-2): 239-247. doi:10.1016/j.ijpharm.2015.12.014
20. Chen L. Wang Y. Zhang J. Hao L. Guo H. Lou H. Zhang D. Bexarotene nanocrystal-Oral and parenteral formulation development, characterization and pharmacokinetic evaluation. Eur J Pharm Biopharm. 2014; 87(1): 160-169. doi:10.1016/j.ejpb.2013.12.005
21. Gadade DD. Pekamwar SS. Cyclodextrin Based Nanoparticles for Drug Delivery and Theranostics. Adv Pharm Bull. 2020; 10(2): 166-183.doi:10.34172/apb.2020.022
22. Dudhipala N. Ettireddy S. Youssef AAA. Puchchakayala G. Cyclodextrin Complexed Lipid Nanoparticles of Irbesartan for Oral Applications: Design, Development, and In Vitro Characterization. Molecules. 2021; 26(24): 7538. doi:10.3390/molecules26247538
23. Kumar L. Suhas BS. Pai GK. Verma R. Determination of Saturated Solubility of Naproxen using UV Visible Spectrophotometer. Research J. Pharm. and Tech. 2015; 8(7): 825-828
24. Bhardwaj S. Shanthi N. Kumar M. Mahato AK. Cyclodextrin Based MTX Nanocrystals: Role in Solubility and Bioavailability Enhancement. Inventi rapid:NDDS. 2018(4): 209-216
25. Gill P. Moghadam TT. Ranjbar B. Differential scanning calorimetry techniques: applications in biology and nanoscience. J Biomol Tech. 2010; 21(4): 167-193.
26. Vidlářová L. Romero GB. Hanuš J. Štěpánek F. Müller RH. Nanocrystals for dermal penetration enhancement - Effect of concentration and underlying mechanisms using curcumin as model. Eur J Pharm Biopharm. 2016; 104: 216-225. doi:10.1016/j.ejpb.2016.05.004
27. Kakran M. Shegokar R. Sahoo NG. Shaal LA. Li L. Müller RH. Fabrication of quercetin nanocrystals: comparison of different methods. Eur J Pharm Biopharm. 2012; 80(1): 113-121. doi:10.1016/j.ejpb.2011.08.006
28. Salamanca CH. Barrera-Ocampo A. Lasso JC. Camacho N. Yarce CJ. Franz Diffusion Cell Approach for Pre-Formulation Characterisation of Ketoprofen Semi-Solid Dosage Forms. Pharmaceutics. 2018; 10(3): 148. doi:10.3390/pharmaceutics10030148
29. Makhlof A. Miyazaki Y. Tozuka Y. Takeuchi H. Cyclodextrins as stabilizers for the preparation of drug nanocrystals by the emulsion solvent diffusion method. Int J Pharm. 2008; 357(1-2): 280-285. doi:10.1016/j.ijpharm.2008.01.025
30. Morakul B. Suksiriworapong J. Chomnawang MT. Langguth P. Junyaprasert VB. Dissolution enhancement and in vitro performance of clarithromycin nanocrystals produced by precipitation-lyophilization-homogenization method. Eur J Pharm Biopharm. 2014; 88(3): 886-896. doi:10.1016/j.ejpb.2014.08.013
31. Srivalli KMR. Mishra B. Preparation and pharmacodynamic assessment of ezetimibe nanocrystals: Effect of P-gp inhibitory stabilizer on particle size and oral absorption. Colloids Surf B Biointerfaces. 2015; 135: 756-764. doi:10.1016/j.colsurfb.2015.08.042
32. Csicsák D. Szolláth R. Kádár S. Ambrus R. Bartos C. Balogh E. et al. The Effect of the Particle Size Reduction on the Biorelevant Solubility and Dissolution of Poorly Soluble Drugs with Different Acid-Base Character. Pharmaceutics. 2023; 15(1): 278. doi:10.3390/pharmaceutics15010278
33. Hussain K. Qamar A. Bukhari NI. Hussain A. Shehzadi N. Qamar S. Parveen S. Impact of Particle-Size Reduction on the Solubility and Antidiabetic Activity of Extracts of Leaves of Vinca rosea. Turk J Pharm Sci. 2019 Sep; 16(3): 335-339. doi.org/10.4274/tjps.galenos.2018.02419
34. Muneer R Hashmet MR. Pourafshary P. Shakeel M. Unlocking the Power of Artificial Intelligence: Accurate Zeta Potential Prediction Using Machine Learning. Nanomaterials (Basel). 2023 Mar 29; 13(7): 1209. doi.org/10.3390/nano13071209
35. Danaei M. Dehghankhold M. Ataei S. Hasanzadeh Davarani F. Javanmard R. Dokhani A. et al.. Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems. Pharmaceutics. 2018; 10(2): 57. doi.org/10.3390/pharmaceutics10020057
36. Sharma K. Nilsuwan K. Ma L. Benjakul S. Effect of Liposomal Encapsulation and Ultrasonication on Debittering of Protein Hydrolysate and Plastein from Salmon Frame. Foods. 2023; 12(4): 761. doi.org/10.3390/foods12040761
37. Ali A. Chiang YW. Santos RM. X-ray Diffraction Techniques for Mineral Characterization: A Review for Engineers of the Fundamentals, Applications, and Research Directions. Minerals. 2022; 12(2): 205. doi.org/10.3390/min12020205
38. Jain AA. Panigrahy RN. Mahale AM. Formulation and Evaluation of Extended Release Metformin Hydrochloride Microspheres by Ionotropic Gelation Technique. Research J. Pharm. and Tech. 2011; 4(7): 1055-1059.
39. Singh M. Barua H. Jyothi VGSS. Dhondale MR. Nambiar AG. Agrawal AK. et al. Cocrystals by Design: A Rational Coformer Selection Approach for Tackling the API Problems. Pharmaceutics. 2023; 15(4): 1161. doi:10.3390/pharmaceutics15041161
40. Sinha B. Köster D. Ruez R. Gonnord P. Bastiani M. Abankwa D. et al. Cells respond to mechanical stress by rapid disassembly of caveolae. Cell. 2011; 144(3): 402-413. doi:10.1016/j.cell.2010.12.031